Treatment of autoimmune disease by oral tolerance to autoantigens

Clinical Immunology and Immunopathology

Volumn 80, Issue 3 II, 1996, Pages

  Whitacre, Caroline C ^a,b   Gienapp, Ingrid E ^a   Meyer, Abbie ^a   Cox, Karen L ^a   Javed, Najma ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; MYELIN BASIC PROTEIN;

AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UVEORETINITIS;

EID: 0029835765     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0139     Document Type: Conference Paper

References (75)

1. Prineas, J. W., and Wright, R. G., Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 38, 409-421, 1978.
2. Hauser, S. L., Dawson, D. M., Lehrich, J. R., Beal, M. F., Kevy, S. V., Propper, R. D., Mills, J. A., and Weiner, H. L., Intensive immunosuppression in progressive multiple sclerosis. N. Engl. J. Med. 308, 173-180, 1983.
3. Weiner, H. L., Hauser, S. L., Hafler, D. A., Fallis, R. J., Lehrich, J. R., and Dawson, D. A., The use of cyclophosphamide in the treatment of multiple sclerosis. Ann. N.Y. Acad. Sci. 436, 373-381, 1985.
4. Hafstein, M. P., Devereux, C., Troiano, R., Zito, G., Vidaver, R., Dowling, P. C., Lavenhar, M., and Cook, S. D., Total lymphoid irradiation in chronic progressive multiple sclerosis. A preliminary report. Ann. N.Y. Acad. Sci. 436, 397-409, 1984.
5. Rose, A. S., Kuzma, J. W., Kurtzke, J. F., Namerow, N. S., Sibley, W. A., and Tourtellotte, W. W., Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo. Neurology (Minneapolis) 20(Supplement), 1-59, 1970.
6. Panitch, H. S., Hirsch, R. L., Schindler, J., and Johnson, K. P., Treatment of multiple sclerosis with gamma Interferon: Exacerbations associated with activation of the immune system. Neurology 37, 1097-1102, 1987.
7. Sheremata, W., Cosgrove, J. B. R., and Eylar, E. H., Cellular hypersensitivity to basic myelin (Al) protein and clinical multiple sclerosis. N. Engl. J. Med. 291, 14-17, 1974.
8. Knight, S. C., Cellular immunity in multiple sclerosis. Br. Med. Bull. 33, 45-50, 1977.
9. Lisak, R. P., and Zweiman, B., In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases. N. Engl. J. Med. 297, 850-853, 1977.
10. Lisak, R. P., Zweiman, B., Burns, J. P., Rostami, A., and Silberberg, D., Immune responses to myelin antigens in multiple sclerosis. Ann. N.Y. Acad. Sci. 436, 221-232, 1984.
11. Allegretta, M., Nicklas, J. A., Sriram, S., and Albertini, R. J., T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247, 718-721, 1990.
12. Ben-Nun, A., Liblau, R. S., Cohen, I., Lehmann, D., Tourner-Lasserve, E., Rosenzweig, A., Jingwu, Z., Raus, J. C. M., and Bach, M. A., Restricted T-cell receptor Vβ gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: Predominant genes vary in individuals. Proc. Natl. Acad. Sci. USA 88, 2466-2470, 1991.
13. Kotzin, B. L., Karuturi, S., Chou, Y. K., Lafferty, J., Forrester, J. M., Better, M., Nedwin, G. E., Offner, H., and Vandenbark, A. A., Preferential T-cell receptor β-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 88, 9161-9165, 1991.
14. Oksenberg, J. R., Panzara, M. A., Begovich, A. B., Mitchell, D., Erlich, H. A., Murray, R. S., Shimonkevitz, R., Sherritt, M., Rothbard, J., Bernard, C. C. A., and Steinman, L., Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68-70, 1993.
15. Paterson, P. Y., and Swanborg, R. H., Demyelinating diseases of the central and peripheral nervous systems. In "Immunological Diseases" (M. Samter, D. W. Talmage, M. M. Frank, K. F. Austen, and H. N. Claman, Eds.), 4th ed., pp. 1877-1916, Little, Brown, & Co., Boston, 1988.
16. Chou, C-H. J., Chou, F. C-H., Kowalski, T. J., Shapira, R., and Kibler, R. F., The major site of guinea pig myelin basic protein encephalitogenic in Lewis rats. J. Neurochem. 28, 115-119, 1977.
17. Zamvil, S. S., and Steinman, L., The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8, 579-621, 1990.
18. Zamvil, S. S., Nelson, P. A., Mitchell, D. J., Knobler, R. L., Fritz, R., and Steinman, L., Encephalitogenic T-cell clones specific for myelin basic protein: An unusual bias in antigen presentation. J. Exp. Med. 162, 2107-2124, 1985.
19. Ben-Nun, A., Wekerle, H., and Cohen, I. R., The rapid isolation of clonable antigen-specific T-lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11, 195-199, 1981.
20. Heber-Katz, E., and Acha-Orbea, H., The V-region disease hypothesis: Evidence from autoimmune encephalomyelitis. Immunol. Today 10, 164-169, 1989.
21. Burns, F. R., Li, X., Shen, N., Offner, H., Chou, Y. K., Vandenbark, A. A., and Heber-Katz, E., Both rat and mouse T-cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Va and Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J. Exp. Med. 169, 27-39, 1989.
22. Urban, J. L., Kumar, V., Kono, D. H., Gomez, C., Horvath, A. J., Clayton, J., Ando, D. G., Sercarz, E. E., and Hood, L., Restricted use of T-cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 54, 577-592, 1988.
23. Acha-Orbea, H., Mitchell, D. J., Timmerman, L., Wraith, D. C., Tausch, G. S., Waldor, M. K., Zamvil, S. S., McDevitt, H. O., and Steinman, L., Limited heterogeneity of T-cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54, 263-273, 1988.
24. Gold, D. P., Offner, H., Sun, D., Wiley, S., Vandenbark, A. A., and Wilson, D. B., Analysis of T-cell receptor β chains in Lewis rats with experimental allergic encephalomyelitis - Conserved complementarity determining region-3. J. Exp. Med. 174, 1467-1476, 1991.
25. Zhang, X-M., and Heber-Katz, E., T-cell receptor sequences from encephalitogenic T cells in adult Lewis rats suggest an early ontogenic origin. J. Immunol. 148, 746-752, 1992.
26. Vandenbark, A. A., Hashim, G., and Offner, H., Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541-544, 1989.
27. Howell, M. D., Winters, S. T., Olee, T., Powell, H. C., Carlo, D. J., and Brostoff, S. W., Vaccination against experimental allergic encephalomyelitis with T-cell receptor peptides. Science 246, 668-670, 1989.
28. Offner, H., Hashim, G. A., and Vandenbark, A. A., T-cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251, 430-432, 1991.
29. Miller, S. D., and Karpus, W. J., The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases. Immunol. Today 15, 356-361, 1994.
30. Kennedy, M. K., Tan, L. J., Dal Canto, M. C., Tuohy, V. K., Lu, A., Trotter, J. L., and Miller, S. D., Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein (PLP) and its encephalitogenic peptides. J. Immunol. 144, 909-915, 1990.
31. Kennedy, M. K., Tan, L. J., Dal Canto, M. C., and Miller, S. D., Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J. Immunol. 145, 117-126, 1990.
32. Tan, L. J., Kennedy, M. K., and Miller, S. D., Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T-cell inhibition. J. Immunol. 148, 2748-2755, 1992.
33. Clayton, J. P., Gammon, G. M., Ando, D. G., Kono, D. H., Hood, L., and Sercarz, E. E., Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T-cell determinant of myelin basic protein. J. Exp. Med. 169, 1681-1691, 1989.
34. Gaur, A., Wiers, B., Liu, A., Rothbard, J., and Fathman, C. G., Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258, 1491-1494, 1992.
35. Wells, H. G., Studies on the chemistry of anaphylaxis (III). Experiments with isolated proteins, especially those of the hen's egg. J. Infect. Dis. 9, 147-171, 1911.
36. Chase, M. W., Inhibition of experimental drug allergy by prior feeding of the sensitized agent. Proc. Soc. Exp. Biol. Med. 61, 257-259, 1946.
37. Thomas, H. C., and Parrott, D. M. V., The induction of tolerance to a soluble protein antigen by oral administration. Immunology 27, 631-639, 1974.
38. Miller, S. D., and Hanson, D. G., Inhibition of specific immune responses by feeding protein antigens. IV. Evidence for tolerance and specific active suppression of cell-mediated immune responses to ovalbumin. J. Immunol. 123, 2344-2350, 1979.
39. Richman, L. K., Chiller, J. M., Brown, W. R., Hanson, D. G., and Vaz, N. M., Enterically induced immunologic tolerance. I. Induction of suppressor T lymphocytes by intragastric administration of soluble proteins. J. Immunol. 121, 2429-2434, 1978.
40. Ngan, J., and Kind, L. S., Suppressor T cells for IgE and IgG in Peyer's patches of mice made tolerant by the oral administration of ovalbumin. J. Immunol. 120, 861-865, 1978.
41. Asherson, G. L., Zembala, M., Perera, M. A. C. C., Mayhew, B., and Thomas, W. R., Production of immunity and unresponsiveness in the mouse by feeding contact sensitizing agents and the role of suppressor cells in the Peyer's patches, mesenteric lymph nodes and other lymphoid tissues. Cell. Immunol. 33, 145-155, 1977.
42. Kagnoff, M. F., Effects of antigen-feeding on intestinal and systemic immune responses. II. Suppression of delayed-type hypersensitivity reactions. J. Immunol. 120, 1509-1513, 1978.
43. Mattingly, J. A., and Waksman, B. H., Immunologic suppression after oral administration of antigen. I. Specific suppressor cells formed in rat Peyer's patches after oral administration of sheep erythrocytes and their systemic migration. J. Immunol. 121, 1878-1883, 1978.
44. Andre, C., Heremans, J. F., Vaerman, J. P., and Cambiaso, C. L., A mechanism for the induction of immunological tolerance by antigen feeding: Antigen-antibody complexes. J. Exp. Med. 142, 1509-1519, 1975.
45. Thompson, H. S. G., and Staines, N. A., Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats. Clin. Exp. Immunol. 64, 581-586, 1986.
46. Nagler-Anderson, C., Bober, L. A., Robinson, M. A., Siskind, G. W., and Thorbecke, G. J., Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc. Natl. Acad. Sci. USA 83, 7443-7446, 1986.
47. Bitar, D. M., and Whitacre, C. C., Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell. Immunol. 112, 364-370, 1988.
48. Higgins, P. J., and Weiner, H. L., Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 140, 440-445, 1988.
49. Griffin, A. C., and Whitacre, C. C., Sex and strain differences in the circadian rhythm fluctuation of endocrine and immune function in the rat: Implications for rodent models of autoimmune disease. J. Neuroimmunol. 35, 53-64, 1991.
50. Javed, N. H., Gienapp, I. E., Cox, K. L., and Whitacre, C. C., Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 155, 1599-1605, 1995.
51. Whitacre, C. C., Bitar, D. M., Gienapp, I. E., and Orosz, C. G., Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J. Immunol. 147, 2155-2163, 1991.
52. Fuller, K. A., Pearl, D., and Whitacre, C. C., Oral tolerance in experimental autoimmune encephalomyelitis: Serum and salivary antibody responses. J. Neuroimmunol. 28, 15-26, 1990.
53. Miller, A., Lider, D., and Weiner, H. L., Antigen-driven by-stander suppression after oral administration of antigens. J. Exp. Med. 174, 791-798, 1991.
54. Lider, O., Santos, L. M. B., Lee, C. S. Y., Higgins, P. J., and Weiner, H. L., Suppression of EAE by oral administration of MBP. II. Suppression of disease and in vitro immune response is mediated by antigen-specific CD8+ T lymphocytes. J. Immunol. 142, 748-752, 1989.
55. Miller, A., Lider, O., Roberts, A. B., Sporn, M. B., and Weiner, H. L., Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering. Proc. Natl. Acad. Sci. USA 89, 421-425, 1992.
56. Khoury, S. J., Hancock, W. W., and Weiner, H. L., Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176, 1355-1364, 1992.
57. Chen, Y., Kuchroo, V. K., Inobe, J. I., Hafler, D. A., and Weiner, H. L., Regulatory T-cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265, 1237-1240, 1994.
58. Chen, Y., Inobe, J. I., and Weiner, H. L., Induction of oral tolerance to myelin basic protein in CD8-depleted mice: Both CD4+ and CD8+ cells mediate active suppression. J. Immunol. 155, 910-916, 1995.
59. Gaur, A., Haspel, R., Mayer, J. P., and Fathman, C. G., Requirement for CD8+ cells in T-cell receptor peptide-induced clonal unresponsiveness. Science 259, 91-94, 1993.
60. Goverman, J., Woods, A., Larson, L., Weiner, L. P., Hood, L., and Zaller, D. M., Transgenic mice that express a myelin basic protein-specific T-cell receptor develop spontaneous autoimmunity. Cell 72, 551-560, 1993.
61. Zhang, A. J., Lee, C. S. Y., Lider, O., and Weiner, H. L., Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J. Immunol. 145, 2489-2493, 1990.
62. Thompson, S. J., Thompson, H. S. G., Harper, N., Day, M. J., Coad, A. J., Elson, C. J., and Staines, N. A., Prevention of pristane-induced arthritis by oral administration of type II collagen. Immunology 79, 152-157, 1993.
63. Nussenblatt, R. B., Caspi, R. R., Mahdi, R., Chan, C-C., Roberge, F., Lider, O., and Weiner, H. L., Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J. Immunol. 144, 1689-1695, 1990.
64. Thurau, S. R., Chan, D-D., Suh, E., and Nussenblatt, R. B., Induction of oral tolerance to S-antigen induced experimental autoimmune uveitis by a uveitogenic 20mer peptide. J. Autoimmun. 4, 507-516, 1991.
65. Singh, V. K., Kalra, H. K., Yamaki, K., and Shinohara, T., Suppression of experimental autoimmune uveitis in rats by the oral administration of the uveitopathogenic S-antigen fragment or a cross-reactive homologous peptide. Cell. Immunol. 139, 81-90, 1992.
66. Vrabec, T. R., Gregerson, D. S., Dua, H. S., and Donoso, L. A., Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides. Autoimmunity 12, 175-184, 1992.
67. Gregerson, D. S., Obritsch, W. F., and Donoso, L. A., Oral tolerance in experimental autoimmune uveoretinitis: Distinct mechanisms of resistance are induced by low versus high-dose feeding protocols. J. Immunol. 151, 5751-5761, 1993.
68. Zhang, Z. Z., Davidson, L., Eisenbarth, G., and Weiner, H. L., Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88, 10252-10256, 1991.
69. Wang, Z-Y., Qiao, J., and Link, H., Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44, 209-214, 1993.
70. Okumura, S., McIntosh, K., and Drachman, D. B., Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis. Ann. Neurol. 36, 704-713, 1994.
71. Peterson, K. E., and Braley-Mullen, H., Suppression of murine experimental autoimmune thyroiditis (EAT) by oral administration of porcine thyroglobulin (PTg). Abstracts of the Ninth International Congress of Immunology #4991, 1995.
72. Sayegh, M. H., Zhang, A. A., Hancock, W. W., Kwok, C. A., Carpenter, C. B., and Weiner, H. L., Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization by skin allografts by orally administered alloantigen. Transplantation 53, 163-166, 1992.
73. Sayegh, M. H., Khoury, S. J., Hancock, W. H., Weiner, H. L., and Carpenter, C. B., Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc. Natl. Acad. Sci. USA 89, 7762-7766, 1992.
74. Weiner, H. L., Mackin, G. A., Matsui, M., Orav, E. J., Khoury, S. J., Dawson, D. M., and Hafler, D. A., Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321-1324, 1993.
75. Trentham, D. E., Dynesius-Trentham, R. A., Orav, E. J., Combitichi, D., Lorenzo, C., Sewell, K. L., Hafler, D. A., and Weiner, H. L., Effects of oral administration of collagen on rheumatoid arthritis. Science 261, 1727-1730, 1993.